Fulphila is administered as a subcutaneous (under-the-skin) injection. It is available in a pre-filled syringe. Treatment with Fulphila should be initiated and supervised by a physician experienced in cancer treatment or blood disorders. Patients or caregivers can be trained to administer the injection at home.
- Timing of Administration: Fulphila is typically given as a single 6 mg subcutaneous injection at least 24 hours after the end of each cycle of cytotoxic chemotherapy. It should not be administered within 14 days before the next cycle of chemotherapy. Your doctor or nurse will provide a specific schedule.
- Preparation:
- Allow the pre-filled syringe to reach room temperature for at least 30 minutes before injection. Do not warm it using heat sources like hot water or a microwave.
- Do not shake the syringe vigorously.
- Inspect the solution for particles or discoloration. The solution should be clear to opalescent and colorless to slightly yellow. Do not use if it is cloudy, discolored, or contains particles.
- Injection Sites: The injection can be given into the thigh, abdomen (at least 2 inches away from the navel), or the outer area of the upper arm (if someone else is giving the injection). Rotate injection sites with each dose.
- Injection Technique (General Subcutaneous):
- Clean the injection site with an alcohol wipe.
- Pinch about 1-2 inches of skin.
- Insert the needle quickly into the pinched skin at a 45- to 90-degree angle.
- Slowly push the plunger until all medication is injected (usually less than 10 seconds).
- Withdraw the needle and release the pinched skin.
- Do not rub the injection site.
- Disposal: The pre-filled syringe is for single-use only. Dispose of the used syringe immediately in an FDA-cleared sharps disposal container.
- Missed Dose: If a dose is missed, contact your doctor, nurse, or pharmacist as soon as possible to determine the appropriate course of action.
Fulphila’s mechanism of action is designed to stimulate the production of infection-fighting white blood cells.
- Granulocyte-Colony Stimulating Factor (G-CSF) Analog: The active substance in Fulphila, pegfilgrastim, is a “pegylated” form of filgrastim. Filgrastim is a recombinant human granulocyte-colony stimulating factor (G-CSF). G-CSF is a naturally occurring protein in the body that regulates the production and release of neutrophils from the bone marrow.
- Stimulates Neutrophil Production: By mimicking the action of natural G-CSF, pegfilgrastim in Fulphila directly stimulates the bone marrow to produce, mature, and release more neutrophils into the bloodstream. This rapid increase in neutrophil count helps to restore the body’s ability to fight off bacterial and fungal infections.
- Pegylation Advantage: The “pegylated” form means that filgrastim has been attached to polyethylene glycol (PEG). This process slows down the removal of pegfilgrastim from the body, allowing it to have a longer duration of action compared to non-pegylated filgrastim. This extended action enables Fulphila to be given as a single dose per chemotherapy cycle, rather than daily injections, improving patient convenience and compliance.
Like all medications, Fulphila can cause side effects. Most commonly reported side effects are generally mild to moderate.
- Very Common Side Effects (may affect more than 1 in 10 people):
- Bone pain: This is the most frequently reported side effect and is generally mild to moderate. It is thought to be related to the increased activity in the bone marrow.
- Common Side Effects (may affect up to 1 in 10 people):
- Pain in extremity (arms or legs)
- Headache
- Nausea, diarrhea, constipation
- Fatigue
- Alopecia (hair loss or thinning)
- Musculoskeletal pain (e.g., back pain, joint pain, muscle aches, neck pain)
- Thrombocytopenia (low platelet count), leukocytosis (high white blood cell count – this is an expected pharmacological effect)
- Injection site reactions (pain, redness, bruising, swelling at the injection site)
- Uncommon / Serious Side Effects (Seek immediate medical attention if any of these occur):
- Splenic Rupture: Rare but potentially fatal, characterized by severe pain in the left upper abdomen or shoulder.
- Acute Respiratory Distress Syndrome (ARDS): Characterized by fever, shortness of breath, cough, and lung infiltrates.
- Serious Allergic Reactions: Including anaphylaxis, angioedema, generalized rash, hives, swelling of the face/lips/tongue/throat, difficulty breathing, or dizziness. These can occur upon initial or subsequent exposure.
- Sickle Cell Crisis: Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders.
- Glomerulonephritis: A type of kidney inflammation, which may manifest as swelling in the face or ankles, blood in the urine, or decreased urination.
- Capillary Leak Syndrome: A rare, severe condition characterized by sudden swelling, feeling faint, and low blood pressure.
- Aortitis: Inflammation of the aorta (the body’s largest artery), with symptoms like fever, abdominal pain, back pain, or general malaise.
- Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis) or Cutaneous Vasculitis: Skin conditions with painful, red, raised lesions.
- Injection Site Reactions (Severe): Significant pain, bruising, or inflammation at the injection site.
It is crucial to report any new, worsening, or concerning symptoms to your healthcare provider immediately.
Careful patient selection and monitoring are essential when using Fulphila.
- Splenic Rupture: Rare cases of splenic rupture, some fatal, have been reported. Patients experiencing left upper abdominal or shoulder pain should be evaluated for an enlarged spleen or splenic rupture.
- Acute Respiratory Distress Syndrome (ARDS): ARDS has been reported in patients receiving G-CSF products. Patients who develop fever, lung infiltrates, or respiratory distress should be evaluated and Fulphila discontinued if ARDS is confirmed.
- Serious Allergic Reactions: Hypersensitivity reactions, including anaphylaxis, can occur. If a serious allergic reaction occurs, Fulphila should be permanently discontinued, and appropriate medical therapy initiated.
- Sickle Cell Disorders: Severe and sometimes fatal sickle cell crises have occurred in patients with sickle cell disease or trait receiving pegfilgrastim. Use with caution and monitor closely.
- Glomerulonephritis: Cases of glomerulonephritis have been reported. If suspected, evaluate for the cause, and consider dose reduction or interruption of therapy.
- Leukocytosis: White blood cell (WBC) counts of 100×109/L or greater have been observed. This is generally transient, but regular monitoring of WBC counts is recommended.
- Aortitis: Aortitis has been reported, potentially as early as the first week of therapy. Manifestations may include fever, abdominal pain, back pain, and increased inflammatory markers.
- Bone Marrow Disorders: Fulphila is not indicated for patients with chronic myeloid leukemia (CML) or myelodysplastic syndromes (MDS), as G-CSF can promote the growth of myeloid cells and potentially worsen these conditions.
- Timing of Administration with Chemotherapy: Adhere strictly to the recommended timing of administration (at least 24 hours after chemotherapy and not within 14 days before the next cycle) to avoid potential potentiation of myelosuppression.
- Latex Sensitivity: The needle cover of the pre-filled syringe may contain dry natural rubber (a derivative of latex), which can cause allergic reactions in latex-sensitive individuals.
- Storage and Handling: Do not freeze or shake Fulphila. Protect from light.
- Pediatric Use: While appropriate studies have shown efficacy in pediatric patients, specific weight-based dosing applies for those weighing less than 45 kg. The pre-filled syringe is not designed for direct administration of doses less than 6 mg.
- Pregnancy and Lactation: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown if Fulphila passes into breast milk. Discuss with a healthcare professional.
While specific drug-drug interaction studies for Fulphila (pegfilgrastim-jmdb) are generally limited, some important considerations and precautions exist, particularly concerning chemotherapy and other myelosuppressive agents. Always inform your doctor and pharmacist about all medications, supplements, and herbal products you are taking.
- Cytotoxic Chemotherapy: Fulphila should not be administered within 14 days before and 24 hours after administration of cytotoxic chemotherapy. This is a critical timing instruction because rapidly dividing myeloid cells (which Fulphila stimulates) are highly sensitive to cytotoxic chemotherapy. Administering Fulphila too close to chemotherapy could potentially worsen myelosuppression or reduce the effectiveness of Fulphila.
- 5-Fluorouracil (5-FU) and Other Antimetabolites: In animal models, concomitant administration of pegfilgrastim with 5-fluorouracil (5-FU) or other antimetabolites has been shown to potentiate myelosuppression. While not specifically evaluated in human clinical trials for Fulphila, this suggests a need for caution.
- Lithium: The potential for interaction with lithium (which also promotes neutrophil release) has not been specifically investigated. However, there is no evidence to suggest such an interaction would be harmful.
- Other Hematopoietic Growth Factors and Cytokines: Interactions with other hematopoietic growth factors or cytokines have not been specifically investigated in clinical trials.
It is crucial to adhere to the prescribed timing of Fulphila administration relative to chemotherapy cycles to maximize its benefits and minimize potential adverse effects.
The standard dosage for Fulphila for chemotherapy-induced neutropenia is a fixed dose, irrespective of body weight (for adults and pediatric patients 45 kg).
- Adults and Pediatric Patients ≥ 45 kg:
- The recommended dose is a single 6 mg subcutaneous injection once per chemotherapy cycle.
- Timing: Administer at least 24 hours after the administration of cytotoxic chemotherapy. Do not administer within 14 days before the next cycle of chemotherapy.
- Pediatric Patients < 45 kg:
- Weight-based dosing applies, and specific guidelines must be followed by a healthcare professional. The pre-filled syringe is not designed for direct administration of doses less than 6 mg.
- Typical weight-based doses (as per some guidelines) might include:
- < 10 kg: 0.1 mg/kg
- 10-20 kg: 1.5 mg
- 21-30 kg: 2.5 mg
- 31-44 kg: 4 mg
- Administration: Administer via subcutaneous injection into the thigh, abdomen, or upper arm.
Always follow your doctor’s instructions precisely regarding the dosage and timing of Fulphila injections.
Fulphila (pegfilgrastim-jmdb) is a prescription-only medication. It cannot be obtained without a valid prescription from a licensed healthcare professional.
- Specialist Oversight: Treatment with Fulphila should be initiated and supervised by a physician experienced in the treatment of cancer or blood disorders. This ensures appropriate diagnosis, monitoring, and management of potential complications.
- Specific Indication: It is indicated for patients receiving myelosuppressive chemotherapy for non-myeloid malignancies who are at risk of febrile neutropenia. It is not for general use.
- Comprehensive Patient Evaluation: Before prescribing, a thorough medical evaluation is necessary to assess the patient’s cancer type, chemotherapy regimen, overall health, and risk factors for adverse effects.
- Patient Training for Self-Administration: If patients are to self-administer Fulphila at home, they (or their caregivers) must receive comprehensive training from a healthcare professional on proper injection technique and safety precautions.
- Reimbursement and Prior Authorization: As a specialty medication, Fulphila often requires prior authorization from insurance providers and may be covered under either medical or pharmacy benefits, depending on the plan.
Therefore, Fulphila is always used under the strict supervision and guidance of a qualified healthcare professional, integrated into a comprehensive cancer treatment plan.
What is Fulphila used for? To reduce the risk of infection (febrile neutropenia) in patients receiving myelosuppressive chemotherapy
2. What is the active ingredient? Pegfilgrastim-jmdb
3. What drug class does it belong to? Granulocyte colony-stimulating factor (G-CSF)
4. Is Fulphila a controlled substance? No
5. Is Fulphila available in generic form? It is a biosimilar to Neulasta
6. How is Fulphila administered? Subcutaneous injection
7. What strengths are available? 6 mg/0.6 mL prefilled syringe
8. What is the usual adult dosage? One 6 mg injection per chemotherapy cycle, at least 24 hours after chemo
9. Can it be used in children? Yes, but dosing is weight-based and requires specialist supervision
10. What are common side effects? Bone pain, headache, fatigue, injection site reactions
11. Can it cause serious reactions? Yes—splenic rupture, acute respiratory distress syndrome (ARDS), allergic reactions
12. Is Fulphila safe during pregnancy? Limited data; use only if benefits outweigh risks
13. Is a prescription required? Yes
14. Is Fulphila available in Pakistan? Not widely; may be accessed via oncology specialty import programs
15. How should it be stored? Refrigerated at 2–8°C; protect from light; do not freeze
16. What precautions should be taken during use? Monitor for splenic enlargement, respiratory symptoms, and allergic reactions
17. What are contraindications? Hypersensitivity to pegfilgrastim or filgrastim products
18. What monitoring is needed during use? CBC with differential, signs of infection, spleen size
19. Can Fulphila be combined with chemotherapy? Yes—given after chemo, not during or immediately before
20. What are similar drugs? Neulasta (pegfilgrastim), Ziextenzo, Udenyca, filgrastim (Neupogen)
